9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

F. Cappuzzo, B. Coudert, R. Wierzbicki, K. Park, F. Custers, G.A. Curbera, G. Giaccone, W. Hilbe, G. Klingelschmitt, T. Ciuleanu
  • European Journal of Cancer Supplements, September 2009, Elsevier
  • DOI: 10.1016/s1359-6349(09)71871-3

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1359-6349(09)71871-3

The following have contributed to this page: Dr Federico Cappuzzo